title: Hsp70 inducer, 17-allylamino-demethoxygeldanamycin, provides neuroprotection via anti-inflammatory effects in a rat model of traumatic brain injury.
abstract: Traumatic brain injury (TBI) is the predominant cause of mortality in young adults and children living in China. TBI induces inflammatory responses; in addition, tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and IL-6 are important pro-inflammatory cytokines. Considering the observation that Hsp-70 overexpression can exert neuroprotection, identifying a drug that is able to induce the upregulation of Hsp70 has the potential to be a promising therapy for the treatment of neurological diseases. Thus, the present study assessed the clinical effectiveness of an anticancer drug and Hsp70 activator, 17-allylamino-demethoxygeldanamycin (17-AAG), to evaluate its potential as a treatment for patients with TBI. The aim of present study was to determine the neuroprotective effects of 17-AAG following trauma and to investigate the underlying mechanisms of action. To establish rat models, rats were subjected to a controlled cortical impact injury and randomly divided into vehicle or 17-AAG groups. In the 17-AAG group, rats were administered with an intraperitoneal injection of 17-AAG (80 mg/kg) immediately following the establishment of TBI. The motor function was measured using Neurologic Severity Score, and neuronal death was evaluated using immunofluorescence. The expression levels of GLT-1, Bcl-2 and Hsp-70 were detected by western blot analysis and the expression levels of inflammatory cytokines were quantified using ELISA. The present study determined that 17-AAG significantly reduced brain edema and motor neurological deficits (P<0.05), in addition to increasing neuronal survival. The aforementioned findings are associated with a downregulation of the expression levels of pro-inflammatory cytokines TNF-α, IL-1β and IL-6. Conversely, no significant changes of glutamate transporter-1 expression were observed. The present results suggest that 17-AAG treatment may provide a neuroprotective effect by reducing inflammation following TBI.
authors.affiliation: Department of Neurology, Donggang Branch of The First Hospital of Lanzhou University, Lanzhou, Gansu 730000, P.R. China.
authors.forename: Youquan
authors.initials: Y
authors.lastname: Gu
authors.affiliation: Department of Neurology, The First Hospital of Lanzhou University, Lanzhou, Gansu 730000, P.R. China.
authors.forename: Jun
authors.initials: J
authors.lastname: Chen
authors.affiliation: Department of Neurology, The First Hospital of Lanzhou University, Lanzhou, Gansu 730000, P.R. China.
authors.forename: Tianhong
authors.initials: T
authors.lastname: Wang
authors.affiliation: Department of Neurology, Donggang Branch of The First Hospital of Lanzhou University, Lanzhou, Gansu 730000, P.R. China.
authors.forename: Chaoning
authors.initials: C
authors.lastname: Zhou
authors.affiliation: Department of Neurology, Donggang Branch of The First Hospital of Lanzhou University, Lanzhou, Gansu 730000, P.R. China.
authors.forename: Zhaodong
authors.initials: Z
authors.lastname: Liu
authors.affiliation: Department of Neurology, Donggang Branch of The First Hospital of Lanzhou University, Lanzhou, Gansu 730000, P.R. China.
authors.forename: Lanhua
authors.initials: L
authors.lastname: Ma
keywords: 17-allylamino-demethoxygeldanamycin; inflammatory cytokines; neuronal death; neuroprotection; rats; traumatic brain injury